Year: 2021

Notice of Meeting of the Holders of the following NotesName ISIN Issuer Issue date Maturity DateHFF150224 XS0195066146 ÍL-sjóður 7.7.2004 15.02.2024HFF150434 XS0195066575 ÍL-sjóður 7.7.2004 15.04.2034HFF150644 XS0195066658 ÍL-sjóður 7.7.2004 15.06.2044Noteholders holding more than one tenth of the aggregate principal amount of the of the outstanding Notes have requested the Issuer, ÍL-sjóður (the Housing Financing Fund, HFF), to convene a Noteholders’ Meeting in order to propose a resolution set out below for approval at a Noteholders’ meeting. The holders of Notes (or their representatives by proxies) forming part of any of the above-mentioned issues are entitled to attend a Meeting of the Noteholders of each of the above issues on Tuesday, December 14, 2021, at the Hilton Reykjavik...

Stockholm, Sweden, November 19, 2021 FIRST NINE MONTHS 2021Annual Recurring Revenue (“ARR”), including long-term service contracts, at the end of the period was MSEK 34.2, up 42% from MSEK 24.0 at the end of Q3 2020. Revenues for the first nine months were MSEK 24.6 (22.2) Gross margin was 75 percent (70) Operating result amounted to MSEK -33.9 (-21.9) Profit after tax amounted to MSEK -34.2 (-24.1) Earnings per share amounted to SEK -0.38 (-0.48)The complete version of the Interim Report for January – September 2021 is attached in this press release and is available on Hoylu’s web site (www.hoylu.com/investor-relations/financial-reports/). For more information, please contact:Stein Revelsby, CEO at Hoylu +1 213 440 2499 Email: sr@hoylu.comKarl Wiersholm, CFO at Hoylu +1 425 829 2316 Email: kw@hoylu.com About Hoylu Hoylu’s...

           Louvain-La-Neuve, Belgium, November 19, 2021 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces that it has signed a contract for the installation of a Proteus®ONE1 proton therapy turnkey solution with the Oncology Reference Center (C.R.O.) in Aviano, Italy. IBA was selected as the preferred supplier following a comprehensive vendor selection process. IBA expects to receive a down payment in the coming weeks. This Proteus®ONE, the 31st to be sold by IBA globally, will be integrated into the current radiotherapy department at C.R.O. and is expected to start treating patients by the end of 2024. Olivier Legrain, Chief Executive Officer of IBA, commented: “We are pleased to sign...

The shares in Mowi ASA will be traded ex-dividend of NOK 1.40 as from today 19 November 2021. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

VANCOUVER, British Columbia, Nov. 19, 2021 (GLOBE NEWSWIRE) — Alpha Lithium Corporation (TSX.V: ALLI) (OTC: APHLF) (Frankfurt: 2P62) (“Alpha” or the “Company”) is very pleased to announce drilling results from its original six-well program. The drilling program was an essential component of Alpha’s initial exploration campaign in the 100% owned, 27,500 hectare, Tolillar Salar located in Salta Province, Argentina. The objectives for the initial campaign were to (i) improve our understanding of the conceptual hydrogeological model of the salar and (ii) determine lithium grades and hydraulic parameters for the brine aquifer. Both objectives were successfully achieved and provided confidence to continue with a second exploration campaign. To date, Alpha has drilled a total of six exploratory holes to varying depths. The first well...

MURRAY, Utah, Nov. 18, 2021 (GLOBE NEWSWIRE) — FinWise Bancorp (“FinWise” or the “Company”), parent company of FinWise Bank (the “Bank”), today announced the pricing of its initial public offering of 3,500,000 shares of its common stock at a public offering price of $10.50 per share. The offering is expected to result in gross proceeds to the Company of approximately $36.8 million. The net proceeds to the Company, after deducting the underwriting discount and estimated offering expenses, are expected to be approximately $31.0 million. The shares are expected to begin trading on November 19, 2021 on the Nasdaq Global Market under the symbol “FINW.” The offering is expected to close on or about November 23, 2021, subject to the satisfaction of customary closing conditions. In addition, the Company has granted...

SEATTLE, Nov. 18, 2021 (GLOBE NEWSWIRE) — Rover Group, Inc. (“Rover”) (NASDAQ: ROVR), the world’s largest online marketplace for pet care, today announced the pricing of its previously announced underwritten public offering of 6,000,000 shares of its Class A common stock by stockholders of Rover that were investors in A Place for Rover, Inc. prior to its merger with Nebula Caravel Acquisition Corp. at a price to the public of $10.00 per share. In addition, certain of the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of Class A common stock on the same terms and conditions. The offering is expected to close on November 23, 2021, subject to customary closing conditions. Rover will not receive any proceeds from any sales of shares by the selling stockholders. Morgan...

ARLINGTON, Va., Nov. 18, 2021 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA, or “Privia Health” or the “Company”), a technology-driven, national physician enablement company that collaborates with medical groups, health plans and health systems, announced the pricing of its previously announced underwritten public offering of 6,000,000 shares of common stock by certain selling stockholders at a public offering price of $29.00 per share. Such selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of the Company’s common stock. The Company will not receive any of the proceeds from the secondary offering. The offering is expected to close on November 23, 2021, subject to customary closing conditions. Goldman Sachs & Co. LLC and J.P. Morgan acted as joint...

LUXEMBOURG, Nov. 18, 2021 (GLOBE NEWSWIRE) — Arrival (NASDAQ: ARVL), announced today the pricing and upsize of its underwritten public follow-on offering (the “Follow-on Offering”). The size of the Follow-on Offering increased from the previously announced 25,000,000 ordinary shares to 32,373,684 ordinary shares at a public offering price of US$9.50 per ordinary share. The Follow-on Offering is being made pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (“SEC”). The Follow-on Offering is expected to close on November 23, 2021, subject to the satisfaction of customary closing conditions. In connection with the Follow-on Offering, Arrival has granted the underwriters the option to purchase up to 4,856,052 additional ordinary shares. All shares are being offered by Arrival. Goldman...